
The pharmaceutical-group Novo Nordisk, a world-leader within diabetes treatment, has taken a decisive step in its efforts to become a dominant factor on the market for the hemophilia-variants, hemophilia A and hemophilia B.
According to Danish newspaper Berlingske, referring to the web-site clinicaltrials.gov, Novo Nordisk has just this week begun phase-3 trials on another hemophilia-product, which means that the company now has 4 products for the treatment of hemophilia in the final phase of trials, informs the newspaper.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app